

IV THERAPY
Closed Needleless Systems



bionector[®]

The Neutral Displacement,
Split Septum, Needleless
Connector



Value Life

Why choose **bionector**?

When deciding which needleless connector to choose for your hospital, it is important to ensure that your choice meets the current global standards for these devices. The global opinion leaders make a number of recommendations in terms of the essential features you should demand when choosing a needleless connector.^(1,2,3,4)

We have designed Bionector to meet these standards and furthermore, our clinical performance studies* provide the evidence to support our claim that Bionector meets these standards.

What do the global opinion leaders recommend?

- A needleless connector that is supported by microbial ingress testing data.⁽¹⁾
- A split septum needleless connector is associated with a lower incidence of CRBSI compared to a mechanical valve needleless connector.^(2,4)
- A needleless connector with a smooth external septum surface with few, if any gaps, that can be more thoroughly disinfected.⁽³⁾
- A tight seal between the septum and the needleless connector housing to reduce or eliminate space for contamination to occur and biofilm to develop.⁽³⁾
- A needleless connector with a direct, that is, straight fluid pathway that facilitates adequate flushing and reduces the internal surface for biofilm development.^(3,4)
- A needleless connector with little or no dead space in the fluid pathway minimizes the surfaces that infusates can contaminate and where biofilm can develop.⁽³⁾
- A needleless connector with the most direct and least tortuous fluid pathway, with preferably no moving parts to reduce the potential risk of CRBSI.⁽³⁾
- A needleless connector that does not require a specific clamping sequence.⁽³⁾
- A luer access mechanical valve needleless connector with little or no blood reflux.^(3,4)

* Refer to the back page for more details.

bionector's features and benefits

bionector®

• Neutral Fluid Displacement ^(3,7)

This means that a specific post flushing clamping sequence is not essential as it is with positive and negative fluid displacement connectors.

• Low Priming Volume ⁽³⁾


Suitable for clinical applications where very low priming volumes and dead space are required. Bionector has a priming volume of just 0.02mL.

• Direct Fluid Pathway ^(3,10)

Proven 'flushable' due to its straight fluid pathway. We can prove that macro and microscopic particles, for example blood, can be successfully flushed from the device.

• Cleanable Membrane ^(1,3,5)

Proven 'cleanable' using the latest disinfectants. Bionector has a smooth easy to swab membrane that fits very tightly into the device's housing.



• MRI Conditional ⁽⁸⁾

Proven not to represent any risk to either patient or practitioner during an MRI of up to 3 Teslas.

• Effective Microbial Barrier ^(1,3,5,6)

Supported by numerous microbiological studies which conclude that microbial ingress does not occur.

• High Pressure Compatibility (CT-Rated)⁽⁹⁾

Approved for use with power injectors.
• Maximum pressure resistance: 350 psi
• Maximum flow rate: > 10 mL/s.

• Split Septum Technology ^(2,3)

Split septum needleless connectors have demonstrated a lower incidence of CRBSI than other designs of connector.

References

1. Food and Drug Administration Agency (FDA), 'Guidance for Industry and FDA staff': Pre-market notification submissions, Microbial Ingress Testing, section 8, page 9, July 11th 2008.
2. Center for Disease Control, 'Guidelines for the Prevention of Intravascular Catheter-Related Infections', Needleless Intravascular Catheter Systems, page 19, No.6. 2011.
3. William R. Jarvis, MD, 'Choosing the Best Design for Intravenous Needleless Connectors to Prevent Bloodstream Infections'. Infection Control Today, July 28th, 2010.
4. The Infusion Nurses Society, Infusion Nurses Standards of Practice; page S32, section 27, Practice Criteria A & B, 2011.
5. Efficacy of the Valve Systems of Needle-Free Closed Connectors, report 67-08, The Health Protection Agency UK, 21st May 2009.
6. An evaluation of Bionector Microbial Integrity, report 65-07, The Health Protection Agency UK, 28th November 2007.
7. Bionector Fluid Displacement Test, report 200700807, Rev 01, Nelson Laboratories USA, 19th April 2007.
8. Bionector MRI Safety Testing, Shellock R & D Services Inc. USA, 19th November 2007.
9. CT Pressure Testing, Laboratoire Central d'Essai, Essai No. RE12176, Vygon SA France, 14th May 2012.
10. Bionector Blood Clearing Evaluation, report GR2225, protocol 2796, Gibraltar Laboratories Inc. USA, 8th December 2006.

A summary of our clinical performance studies are detailed in the '**bionector**[®] Clinical Performance Studies brochure'.* The full protocols and results are available in '**The bionector**[®] Electronic Handbook'.* Please contact us directly or request copies directly from your local Sales Executive.

Technical specifications	
The device contains no latex or dry natural rubber	Yes
Maximum number of activations	150
Flow rate at gravity	105mL/min
Priming volume	0.02mL
MRI conditional	Yes
Blood compatible	Yes
Lipids resistant	Yes
Alcohol resistant	Yes
Chlorhexidine resistant	Yes

- Do not place a cap, plug or obturator of any sort on Bionector other than a disinfecting cap.
- Do not use a needle to access Bionector.
- Remember to clean Bionector prior to access.

For further information, please contact: customerservice@vygonusa.com.

The specifications shown in this leaflet are for information only and are not, under any circumstances, of a contractual nature.

Vygon USA - 2750 Morris Road - Suite A200 • Lansdale, PA 19446
 Phone: 800.473.5414
 Fax: 215.672.6740
www.vygonusa.com

